172 related articles for article (PubMed ID: 10326045)
1. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
Carrieri MP; Moatti JP; Vlahov D; Obadia Y; Reynaud-Maurupt C; Chesney M
J Epidemiol Community Health; 1999 Jan; 53(1):4-8. PubMed ID: 10326045
[TBL] [Abstract][Full Text] [Related]
2. Barriers to antiretroviral treatment access for injecting drug users living with HIV in Chennai, South India.
Chakrapani V; Velayudham J; Shunmugam M; Newman PA; Dubrow R
AIDS Care; 2014; 26(7):835-41. PubMed ID: 24283220
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users.
Bouhnik AD; Moatti JP; Vlahov D; Gallais H; Dellamonica P; Obadia Y;
J Epidemiol Community Health; 2002 May; 56(5):349-53. PubMed ID: 11964431
[TBL] [Abstract][Full Text] [Related]
4. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
[TBL] [Abstract][Full Text] [Related]
5. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs.
Escaffre N; Morin M; Bouhnik AD; Fuzibet JG; Gastaut JA; Obadia Y; Moatti JP;
AIDS Care; 2000 Dec; 12(6):723-30. PubMed ID: 11177451
[TBL] [Abstract][Full Text] [Related]
6. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union.
Wolfe D
Int J Drug Policy; 2007 Aug; 18(4):246-54. PubMed ID: 17689372
[TBL] [Abstract][Full Text] [Related]
7. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
Reynaud-Maurupt C; Carrieri MP; Gastaud JA; Pradier C; Obadia Y; Moatti JP
AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779
[TBL] [Abstract][Full Text] [Related]
8. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
[TBL] [Abstract][Full Text] [Related]
9. Barriers to use of free antiretroviral therapy in injection drug users.
Strathdee SA; Palepu A; Cornelisse PG; Yip B; O'Shaughnessy MV; Montaner JS; Schechter MT; Hogg RS
JAMA; 1998 Aug; 280(6):547-9. PubMed ID: 9707146
[TBL] [Abstract][Full Text] [Related]
10. Self-reported antiretroviral therapy in injection drug users.
Celentano DD; Vlahov D; Cohn S; Shadle VM; Obasanjo O; Moore RD
JAMA; 1998 Aug; 280(6):544-6. PubMed ID: 9707145
[TBL] [Abstract][Full Text] [Related]
11. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.
Rompalo AM; Shah N; Mayer K; Schuman P; Klein RS; Smith DK; Vlahov D
J Acquir Immune Defic Syndr; 2001 Sep; 28(1):28-34. PubMed ID: 11579274
[TBL] [Abstract][Full Text] [Related]
12. Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care.
Gardner LI; Holmberg SD; Moore J; Arnsten JH; Mayer KH; Rompalo A; Schuman P; Smith DK;
J Acquir Immune Defic Syndr; 2002 Jan; 29(1):69-75. PubMed ID: 11782593
[TBL] [Abstract][Full Text] [Related]
13. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users.
Ding L; Landon BE; Wilson IB; Wong MD; Shapiro MF; Cleary PD
Arch Intern Med; 2005 Mar; 165(6):618-23. PubMed ID: 15795336
[TBL] [Abstract][Full Text] [Related]
14. Injecting drug use in pregnant HIV-infected women in Europe.
Thorne C; Newell ML
Med Wieku Rozwoj; 2006; 10(4):1005-16. PubMed ID: 17426368
[TBL] [Abstract][Full Text] [Related]
15. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
Carrieri MP; Vlahov D; Dellamonica P; Gallais H; Lepeu G; Spire B; Obadia Y
Drug Alcohol Depend; 2000 Jul; 60(1):51-4. PubMed ID: 10821989
[TBL] [Abstract][Full Text] [Related]
16. Medication therapy among intravenous drug users (IDUs) with HIV infection.
Smith PC; Page JB
AIDS Patient Care STDS; 1996 Apr; 10(2):101-10. PubMed ID: 11361686
[TBL] [Abstract][Full Text] [Related]
17. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
18. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.
Moore RD; Keruly JC; Chaisson RE
J Acquir Immune Defic Syndr; 2004 Jan; 35(1):46-51. PubMed ID: 14707791
[TBL] [Abstract][Full Text] [Related]
19. Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users.
Carrieri MP; Tamalet C; Vlahov D; Yahi N; Chesney M; Moatti JP
Addict Biol; 1999 Apr; 4(2):197-202. PubMed ID: 20575786
[TBL] [Abstract][Full Text] [Related]
20. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
